Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI

Jianfeng Du,1 Jing Liu,1 Han-Zhong Feng,2 M. M. Hossain,2 Nariman Gobara,1 Chi Zhang,1 Yuejin Li,1 Pierre-Yves Jean-Charles,1 Jian-Ping Jin,2 and Xu-Pei Huang1

1Department of Biomedical Science and Center for Molecular Biology and Biotechnology, University of Miami Miller School of Medicine Boca Regional Campus, Florida Atlantic University, Boca Raton, Florida; and 2Section of Molecular Cardiology, Evanston Northwestern Healthcare and Northwestern University Feinberg School of Medicine, Evanston, Illinois

Submitted 20 December 2007; accepted in final form 9 April 2008

Ru J, Liu J, Feng HZ, Hossain MM, Gobara N, Zhang C, Li Y, Jean-Charles PY, Jin JP, Huang XP. Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI. Am J Physiol Heart Circ Physiol 294: H2604–H2613, 2008. First published April 11, 2008; doi:10.1152/ajpheart.91506.2007.—Transgenic mice were generated in our laboratory by transgenic expression of cTnI193His mice. The objective of this study was to assess cardiac function during the development of diastolic dysfunction and to gain insight into the pathophysiological impact of the RCM cTnI mutation. Cardiac function and pathophysiological changes were monitored in cTnI193His mice and wild-type littermates for a period of 12 mo. It progressed gradually from abnormal relaxation to diastolic dysfunction characterized with high-resolution echocardiography by a reversed E-to-A ratio, increased deceleration time, and prolonged isovolumetric relaxation time. At the age of 12 mo, cardiac output in cTnI193His mice was significantly declined, and some transgenic mice showed congestive heart failure. The negative impact of cTnI193His on ventricular contraction and relaxation was further demonstrated in isolated mouse working heart preparations. The main morphological change in cTnI193His myocytes was shortened cell length. Dobutamine stimulation increased heart rate in cTnI193His mice but did not improve CO. The cTnI193His mice had a phenotype similar to that in human RCM patients carrying the cTnI mutation characterized morphologically by enlarged atria and restricted ventricles and functionally by diastolic dysfunction and diastolic heart failure. The results demonstrate a critical role of the COOH-terminal domain of cTnI in the diastolic function of cardiac muscle.

troponin I; cardiac relaxation; Doppler echocardiography; working heart function

CARDIOMYOPATHIES ARE DISORDERS that primarily affect cardiac muscles and are associated with varying degrees of cardiac dysfunction. On the basis of morphology and pathophysiological changes, cardiomyopathies may be classified into three major subtypes: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and restrictive cardiomyopathy (RCM). Among these, RCM shows the worst prognosis. Some cardiomyopathies are now characterized as “sarcemeric diseases” on the basis of evidence that mutations in sarcemeric proteins are causal. Contractile sarcemeric protein mutations, truncations, or deletion have been identified for various cardiomyopathies in humans or experimental animals (17, 23, 27, 38, 41, 43).

The cardiac sarcomere consists of a highly ordered assembly of myosin thick filaments, actin thin filaments, and associated proteins such as tropomyosin and troponin C, T, and I. Cardiac troponin I (cTnI) is the inhibitory subunit of the troponin complex, which binds to actin-tropomyosin and prevents muscle contraction by inhibition of actin-tropomyosin-activated myosin (actomyosin) ATPase (49). Many clinical and experimental studies have shown that TnI mutations are associated with HCM (19, 22, 31, 42). Recently, a linkage study has, for the first time, demonstrated that idiopathic RCM can be a part of the clinical expression of cTnI mutation (30). A point mutation in the human cTnI gene results in an amino acid substitution (R192H in humans) in the COOH-terminal region of cTnI. It is important to note that the R192H mutation is located in the COOH-terminal region that is highly conserved and required for the full inhibitory action of cTnI (10, 20, 28). The first transgenic (TG) mouse model (cTnI193His mice) carrying the RCM cTnI mutation (Arg193His in mouse cTnI protein, cTnI-R193H) was recently created in our laboratory (8). In preliminary studies, we reported (8) that the phenotype of the cTnI193His mice is very similar to the clinical features of RCM patients carrying the same cTnI mutation. It includes dilated atria and a decreased left ventricular end-diastolic dimension (LVEDD) without significant changes in systolic function (8). However, the molecular mechanism underlying the cTnI mutation-caused RCM is still unknown. The cardiac function, in particular the diastolic function, in the TG mice expressing the RCM cTnI mutation remained to be characterized in order to understand the development of the disease and to find the earliest and most sensitive signs in the TG mice.

In the present study, we used in vivo cardiac function measurements on cTnI193His mice over a period of 12 mo and analyzed the effect of cTnI-R193H on cardiac function in TG mouse hearts, using ex vivo isolated working heart preparations. The results demonstrated that impaired relaxation and restrictive physiology are the main manifestations in TG mice carrying RCM TnI mutation characterized morphologically by enlarged atria and restricted ventricles and functionally by diastolic dysfunction and diastolic heart failure.

METHODS

RCM cTnI193His transgenic mice. The mice used in this study were generated in our laboratory by transgenic expression of cTnI193His mutant protein in the heart under the α-myosin heavy chain promoter

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Address for reprint requests and other correspondence: X. Huang, Dept. of Biomedical Science, Florida Atlantic Univ., 777 Glades Rd., Boca Raton, FL 33431 (e-mail: xhuang@fau.edu).
and maintained as a pathogen-free colony at Florida Atlantic University at Boca Raton, FL. The transgenic construction and genotyping were described previously (8). Wild-type (WT) littermates were used as controls in the present study. This investigation conforms to the Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, revised 1996) and was in accordance with the protocols approved by the Institutional Animal Care and Use Committees at Florida Atlantic University and Evanston Northwestern Healthcare.

Monoclonal anti-TnI antibodies. The mouse monoclonal antibody (MAb) TnI-1 was previously developed by immunization with purified chicken fast TnI (20). TnI-1 recognizes fast, slow, and cardiac TnIs at an epitope conserved in the COOH-terminal region (20).

MAb 4H6 was developed by immunization of the Balb/c mouse with a central fragment of mouse cTnI (amino acids 30-191) expressed in Escherichia coli. The purification of the cTnI30-191 fragment was carried out as described previously (2). Fusion with the SP2/0 myeloma cell line, hybridoma screening, and limiting dilution subclonings were performed as described previously (20). Immunoglobulin isotyping determined that MAb 4H6 is an IgG2b.

SDS-PAGE and Western blotting. Whole cardiac muscle was homogenized in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing 2% SDS to extract myofilament proteins. The samples were resolved by 14% Laemmli SDS-PAGE with an acrylamide-to-bisacrylamide ratio of 180:1 and a Bio-Rad mini-Protein II system, and the protein bands were transferred to a nitrocellulose membrane with a Bio-Rad Lab semidyed electrotransfer apparatus. The nitrocellulose membrane was blocked with 1% bovine serum albumin in Tris-buffered saline (TBS; 150 mM NaCl, 50 mM Tris-HCl, pH 7.5) and incubated with MAb TnI-1 against the COOH terminus of TnI (2) and MAb 4H6 against an epitope in the central region of TnI diluted in TBS containing 0.1% bovine serum albumin. The subsequent washes, incubation with alkaline phosphatase-labeled anti-mouse IgG second antibodies (Sigma), and 5-bromo-4-chloro-3-indolyl phosphate-nitro blue tetrazolium substrate reaction were carried out as described previously (2).

A double-transgenic mouse line (cTnI KO+R193H) was produced by crossbreeding of the cTnI-R193H TG mice with a cTnI gene knockout mouse line (18) to express the cTnI-R193H transgene on a cTnI gene knockout background. Similar to the cTnI gene knockout mice, the double-transgenic mice die 18 days after birth when slow TnI ceases expression in the heart, indicating a severe defect in the function of cTnI-R193H. Nonetheless, 16-day-old postnatal cardiac muscle samples from the double-transgenic mice were used in Western blotting to test the reactivity of the anti-cTnI MAb against cTnI-R193H in the absence of wild-type cTnI.

Ser23/24 phosphorylation status of cTnI was determined in cardiac muscle samples from TG or WT mice by Western blotting using antibodies that detect the phosphorylated form of cTnI (Abcam, Cambridge, MA). Three WT and three TG mice were used to measure the cTnI basal phosphorylation status, and three WT and three TG mice were used to measure the cTnI phosphorylation status after dobutamine treatment (1.5 μg/g body wt ip). Myofibril proteins were isolated with a tissue homogenizer in a lysis buffer (mM: 100 KCl, 10 imidazole, 2 EGTA, 1 MgCl2, pH 7.0) containing protease/phosphatase inhibitors (protease inhibitor cocktail and phosphatase inhibitor cocktail 2 from Sigma). To control for equal protein loading on the gels, cTnI MBAs (4H6) were used to quantify cTnI concentrations.

Western blots were scanned at 600 dpi for densitometric quantification with NIH Image 1.61 software.

In vivo transnathoracic cardiac imaging with echocardiography. All echocardiography measurements were performed according to the standards established in human echocardiography (9, 37, 40). A Verov 770 High-Resolution In Vivo Imaging System (VisualSonics, Toronto, ON, Canada) was used to perform echocardiography studies as described previously (8, 25).

Doppler echocardiography analysis in mice. As previously described, echocardiograph images were acquired in TG and WT mice with the use of a high-resolution (40 MHz) transducer with a digital ultrasonic system. Pulse Doppler images were collected with the apical four-chamber view to record the mitral Doppler flow spectra. The Doppler sample volume was placed at the center of the orifice and at the tip level of the valves for the highest velocities. However, for measurement of the left ventricular systolic and diastolic time intervals, the Doppler sample volume was moved slightly toward the left ventricular outflow tract to intersect with both the mitral inflow and the left ventricular outflow in the same recording. Pulse wave Doppler tissue imaging (DTI) was also performed on experimental animals by activating the DTI function in Vevo 770 echocardiography. Sample volume was measured at the septal side of the mitral annulus. Early (E') and late (A') diastolic mitral annulus velocity and the ratio of E' to A' were determined. Both mitral pulse Doppler and DTI data were collected on six TG mice and six WT mice from the age of 2 mo to 12 mo. Data analysis was performed off-line with the use of a customized version of Vevo 770 Analytic Software.

![Fig. 1. Expression of cardiac troponin I (cTnI)-R193H in transgenic (TG) mouse hearts. A: Western blot showed that whereas MAb 4H6 against an epitope in the central region of cTnI polypeptide recognized both wild-type (WT) cTnI and cTnI-R193H, MAb TnI-1 against the COOH terminus of TnI recognized only WT cTnI but not cTnI-R193H expressed on an endogenous cTnI knockout (KO) background. The expression of slow TnI in the 16-day-old cardiac muscle was detectable by MAb TnI-1 but not 4H6, consistent with 4H6's specificity to cTnI as shown by its lack of reaction to slow and fast TnIs in the soleus muscle. B: SDS-PAGE and Western blots showed that while the overall protein profile and the level of total cTnI (detected by MAb 4H6) did not change in the TG hearts compared with the WT control, the level of WT cTnI decreased in the TG hearts (detected by the TnI-1 blot). The Western blot using anti-cardiac troponin T (TnT) MAb CT3 (3) showed no change in cardiac TnT. MHC, myosin heavy chain. C: densitometry quantification confirmed the decreased level of WT cTnI in the TG hearts due to the replacement by cTnI-R193H. Data are means ± SE. *P < 0.05, n = 3 mice in each group.](http://ajpheart.physiology.org/)

AJP-Heart Circ Physiol • VOL 294 • JUNE 2008 • www.ajpheart.org
Cardiac function of TG and WT mice was measured at 12 mo of age with Langendorff-Neely isolated working heart preparations as described previously (2, 16) at various preloads from 5 to 20 mmHg and a constant afterload of 90 mmHg. Mice were injected intraperitoneally with 100 U heparin and anesthetized with intraperitoneal injection of 100 mg/kg pentobarbital. The thoracic cavity was opened by a transverse incision to access and rapidly isolate the heart. The aorta was cannulated with a modified 18-gauge needle previously primed with perfusion fluid to avoid coronary air emboli. Retrograde perfusion through the aorta was initiated within 3 min after the thoracic cavity was opened. The hearts were perfused with a modified Krebs-Henseleit bicarbonate buffer (mM: 118 NaCl, 4.7 KCl, 2.25 CaCl2, 2.25 MgSO4, 1.2 KH2PO4, 0.32 EGTA, 25 NaHCO3, 1.5 D-glucose, and 2 sodium pyruvate, pH 7.4) aerated with 95% O2-5% CO2 at 37°C. After the Langendorff perfusion was established, the pulmonary artery and veins were exposed by further dissections. A modified 16-gauge needle was used to cannulate the pulmonary vein and left atria. A 30-gauge needle was used to puncture the left ventricle wall via the apex for the insertion of a 1.2-Fr pressure-volume catheter (model 898B, Scisense, London, ON, Canada). Intra-left ventricular placement of the catheter was confirmed by the pressure and volume values recorded. The pulmonary artery was cannulated with PE-50 tubing to collect right ventricular output from coronary effluent.

The heart was then switched to the working mode by perfusion from the left atrium. Function of the isolated working hearts was

Fig. 2. Mortality rate and cardiac histological examination in TG and WT mice. A: mortality rate was recorded in 15 WT and 15 TG mice until the age of 14 mo. B: hematoxylin and eosin staining in cardiac histological sections in TG and WT mice at age of 10 mo did not show any significant hypertrophy or ventricular dilation.

**Functional measurement of isolated working mouse hearts.** Cardiac function of TG and WT mice was measured at 12 mo of age with Langendorff-Neely isolated working heart preparations as described previously (2, 16) at various preloads from 5 to 20 mmHg and a constant afterload of 90 mmHg. Mice were injected intraperitoneally with 100 U heparin and anesthetized with intraperitoneal injection of 100 mg/kg pentobarbital. The thoracic cavity was opened by a transverse incision to access and rapidly isolate the heart. The aorta was cannulated with a modified 18-gauge needle previously primed with perfusion fluid to avoid coronary air emboli. Retrograde perfusion through the aorta was initiated within 3 min after the thoracic cavity was opened. The hearts were perfused with a modified Krebs-Henseleit bicarbonate buffer (mM: 118 NaCl, 4.7 KCl, 2.25 CaCl2, 2.25 MgSO4, 1.2 KH2PO4, 0.32 EGTA, 25 NaHCO3, 1.5 D-glucose, and 2 sodium pyruvate, pH 7.4) aerated with 95% O2-5% CO2 at 37°C. After the Langendorff perfusion was established, the pulmonary artery and veins were exposed by further dissections. A modified 16-gauge needle was used to cannulate the pulmonary vein and left atria. A 30-gauge needle was used to puncture the left ventricle wall via the apex for the insertion of a 1.2-Fr pressure-volume catheter (model 898B, Scisense, London, ON, Canada). Intra-left ventricular placement of the catheter was confirmed by the pressure and volume values recorded. The pulmonary artery was cannulated with PE-50 tubing to collect right ventricular output from coronary effluent.

The heart was then switched to the working mode by perfusion from the left atrium. Function of the isolated working hearts was
measured at 37°C and 480 beats/min controlled by pacing through an isolated stimulator (World Precision Instrument, A365). Aortic flow and coronary effluent were measured in real time by counting drops with Chart software (AD Instruments, Colorado Springs, CO). The aortic pressure was measured with an MLT844 pressure transducer (Capto, Horten, Norway) attached to the aortic cannula. Heart rate, intraventricular pressure, maximum rate of left ventricle pressure development (∆dP/∆t max), and left ventricle volume measurements were obtained through the calibrated pressure-volume catheter. The analog signal was amplified with an ML110 Bridge Amplifier (AD Instruments), sampled at 1,000 Hz by a Powerlab/16 SP digital data archiving system (AD Instruments), and stored on computer disk for subsequent analysis (2, 16). Stroke volume (μl/mg heart tissue) was calculated as the sum of aortic flow and coronary effluent, normalized to heart rate. Time to peak pressure, time to 50% peak pressure, and relaxation time at 75% total relaxation were measured from the left ventricle pressure traces.

Morphology measurement of isolated cardiac myocytes. Cardiac myocytes were isolated from 10-mo-old TG and WT mice with a Langendorff perfusion cell isolation system (Cellutron). The myocytes were cultured in mouse myocyte culture medium provided by the same company, and cell length and width were measured immediately after isolation in viable myocytes with a clear striated sarcomere pattern with an Olympus IX 71 microscope; 150 myocytes from 4 separated TG or WT heart preparations were examined.

β-Adrenergic stress assays. For assessment of left ventricular systolic and diastolic dynamics, B-mode, M-mode, and Doppler echocardiography were performed at rest and after intraperitoneal bolus injection of the β-receptor agonist dobutamine (1.5 μg/g body wt). Assays were performed on five TG and five WT mice.

Statistics. All results are presented as means ± SE. ANOVA and Student’s t-test were used to determine statistical significance. Statistical significance was set at P < 0.05.

RESULTS

To investigate the functional effect of cTnI-R193H, it is essential to estimate its incorporation level in TG mouse

Fig. 5. General patterns of mitral inflow and mitral annulus velocity observed from normal to restrictive physiology in TG mice. TDI, tissue-Doppler imaging.

Fig. 6. Summary of Doppler echocardiography measurements of mitral inflow patterns and left ventricular (LV) diastolic function in WT and TG mice. A: LV IVCT measured by mitral impulse Doppler represents a contraction function of the LV. B: LV IVRT measured by mitral impulse Doppler represents a diastolic function of the LV. IVCT and IVRT measurements were performed as illustrated in Fig. 3. Three to five cardiac cycles were averaged for each experimental animal. C: cardiac output (CO) measurement in TG and WT mice indicates that CO decreased significantly in TG mice at age of 12 mo. D: early wave DT represents an early ventricular rapid filling rate. Data are means ± SE from 6 mice per group. *P < 0.05.
cardiac myofilaments. The SDS-PAGE mobility of the mutant protein cTnI-R193H is identical to that of the WT cTnI. However, the Western blot in Fig. 1A demonstrated that the cTnI-R193H mutation completely abolished the binding of MAB TnI-1, which is known to recognize a COOH-terminal epitope (20). Consistent with this, we showed previously (20) that the COOH-terminal truncated cTnI (1-192) (50) lost reactivity to TnI-1. Therefore, TnI-1 provides a useful tool in the quantification of cTnI-R193H overexpressed in TG mouse hearts.

By comparing the TnI-1 blot detecting only endogenous WT cTnI and the MAB 4H6 blot detecting both WT and cTnI-R193H, we determined the mutant cTnI replacement rate in TG mouse cardiac muscle. The 4H6 Western blots showed similar levels of total cTnI in the TG and control hearts, while the TnI-1 blot detected decreased levels of WT cTnI in the TG hearts due to the incorporation of cTnI193His (Fig. 1B). Densitometry of the Western blots showed that the replacement rate of mutant cTnI in cTnI193His cardiac myocytes is ~25–30% (Fig. 1C). This estimate is consistent with the results obtained from RT-PCR and two-dimensional gel measurements (8), and the confirmed mutant protein replacement rate in the TnI193His TG mouse hearts is similar to that of a previously reported cTnI146Gly (19).

The mortality rate of cTnI193His mice was monitored for a period of 14 mo, and it was higher than that of WT control mice. The survival rate in TG mice at age of 14 mo was ~70%, while no death was found in 15 WT mice at the same age (Fig. 2A). Autopsy examination revealed enlarged livers in some of the transgenic mice at 10 mo of age. However, neither significant hypertrophy nor ventricular dilation was detected in heart samples examined with histological assays (Fig. 2B).

Table 1. Doppler-echocardiography data from cTnI transgenic and wild type mice

<table>
<thead>
<tr>
<th>Parameters</th>
<th>2 mo</th>
<th>4 mo</th>
<th>6 mo</th>
<th>12 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WT cTnI193His</td>
<td>WT cTnI193His</td>
<td>WT cTnI193His</td>
<td>WT cTnI193His</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>21.3±0.6</td>
<td>35.3±1.5</td>
<td>39.0±1.0</td>
<td>48.9±9.0</td>
</tr>
<tr>
<td>Heart weight, mg</td>
<td>23.0±1.0</td>
<td>35.5±1.8</td>
<td>41.3±1.2</td>
<td>42.0±5.0</td>
</tr>
<tr>
<td>HW/BW, mg/g</td>
<td>23.7±12.3</td>
<td>209.6±16.3</td>
<td>4.45±0.28</td>
<td>4.73±0.24</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>421±27</td>
<td>444±23</td>
<td>474±24</td>
<td>487±120</td>
</tr>
<tr>
<td>Echo-ECG</td>
<td>421±27</td>
<td>444±23</td>
<td>474±24</td>
<td>487±120</td>
</tr>
<tr>
<td>End-diastolic LV PW, mm</td>
<td>0.98±0.1</td>
<td>0.97±0.2</td>
<td>1.01±0.2</td>
<td>1.02±0.2</td>
</tr>
<tr>
<td>LV EDV, mm</td>
<td>28.7±1.2</td>
<td>2.97±0.2</td>
<td>2.88±0.2</td>
<td>2.90±0.2</td>
</tr>
<tr>
<td>LV EF, %</td>
<td>61.5±5.8</td>
<td>60.3±4.3</td>
<td>59.1±5.8</td>
<td>59.3±4.1</td>
</tr>
<tr>
<td>Mitral Doppler</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E velocity, mm/s</td>
<td>500±54</td>
<td>638±162</td>
<td>595±106</td>
<td>642±78</td>
</tr>
<tr>
<td>A velocity, mm/s</td>
<td>377±47</td>
<td>360±30</td>
<td>500±59</td>
<td>484±128</td>
</tr>
<tr>
<td>E/A</td>
<td>1.3±0.1</td>
<td>1.2±0.3</td>
<td>1.2±0.1</td>
<td>1.3±0.2</td>
</tr>
<tr>
<td>DTI</td>
<td>21.2±0.7</td>
<td>19.5±6.3</td>
<td>17.8±3.2</td>
<td>16.8±0.9</td>
</tr>
<tr>
<td>E' velocity, mm/s</td>
<td>15.0±0.7</td>
<td>12.7±3.0</td>
<td>16.2±1.9</td>
<td>13.9±1.8</td>
</tr>
<tr>
<td>E'/A'</td>
<td>1.5±0.1</td>
<td>1.5±0.2</td>
<td>1.1±0.6</td>
<td>1.2±0.1</td>
</tr>
</tbody>
</table>

Values are means ± SD from 5 wild-type (WT) and 5 cardiac troponin I (cTnI193His) mice at each time point from 2 to 12 mo of age. HW, heart weight; BW, body weight; LV, left ventricle; PW, posterior wall thickness; LV EDV, LV end-diastolic dimension; LV EDV, LV end-systolic dimension; EF, ejection fraction; DTI, Doppler tissue imaging. *P < 0.05, significant difference between measurements in cTnI193His mice compared with WT littermates at the same age.
age, indicating impaired left ventricular relaxation resulting in diastolic dysfunction (Fig. 6D). Interestingly, isovolumetric contraction time (IVCT), defined as the interval between mitral valve closure and aortic valve opening, was not changed significantly in TG and WT mice throughout the 12-mo period of our study (Fig. 6A), whereas isovolumetric relaxation time (IVRT), defined as the interval between aortic valve closure and mitral valve opening, was significantly prolonged in TG mice starting at age of 4 mo (Fig. 6B). The data indicate that decreased LVEDD and prolonged IVRT are the first signs in cTnI<sup>193His</sup> hearts. This is consistent with previous reports demonstrating that IVRT is the most sensitive Doppler index to detect impaired relaxation because it is first to become abnormal (11, 12). Cardiac output (CO) did not show significant change in TG mice until the age of 12 mo (Fig. 6C), consistent with the changes in ejection fraction (Table 1).

To further evaluate the effect of cTnI-R193H on myocardial function in the absence of neurohumoral influences, isolated working heart function was measured at 90-mmHg afterload and preloads of 5, 8, 10, 12.5, 15, and 20 mmHg. The 12-mo-old TG mouse hearts showed a tendency of decreased stroke volume (Fig. 7A). The data in Fig. 7B further showed a reduced response of the left ventricular end-diastolic volume (EDV) in the TG hearts to increases in preload. To quantitatively demonstrate the impaired contraction as well as relaxation of the cTnI<sup>193His</sup> hearts, the data summarized in Fig. 7, C–E, revealed that compared with WT controls the TG hearts had decreased contractile and relaxation velocities and prolonged systolic and diastolic time parameters. It is worth noting that the TG hearts had less increase in left ventricular EDV and stroke volume compared with WT hearts in response to increases in preload, suggesting a reduced cardiac compliance (Fig. 7, A and B). The functional data obtained in isolated ex vivo working hearts are consistent with the results obtained from the in vivo echocardiography measurements.

On the basis of the functional characterization, the impaired relaxation and restrictive physiology are the main manifestations in transgenic mice carrying the TnI-R193H mutation. Consistent with this, cardiac myocyte morphology under relaxing conditions indicated that the cardiac myocytes isolated

![Fig. 7. Cardiac function measured in isolated working heart preparations. Isolated working heart function was measured at 90-mmHg afterload and preloads of 5, 8, 10, 12.5, 15, and 20 mmHg. A: decrease in the stroke volume of the TG hearts normalized by heart weight compared with the WT controls. B: reduced response of the LV end-diastolic volume (LVEDV) in the TG hearts to the increases in preload. C and D: maximum velocity of LV pressure development (± dp/dt<sub>max</sub>). These velocity changes are consistent with changes in duration of the contractile and relaxation phases shown in E. Data are means ± SE. *P < 0.05, **P < 0.01 by independent t-test. n = 3 for each group.](http://ajpheart.physiology.org/)
from cTnI^{193His} mice were 17% shorter but 15% wider compared with the myocytes from WT mice at the same age (P < 0.05) (Fig. 8, A and B). This result is consistent with the data from cultured myocytes carrying the cTnI-R193H mutation, suggesting a higher basal tone in the myocytes containing cTnI-R193H (7).

To assess whether changes in cTnI phosphorylation are associated with the relaxation impairment in cTnI^{193His} mice, we examined Ser23/24 phosphorylation in cTnI, which has been reported to play a major role in regulation of cardiac myofilament calcium sensitivity and relaxation (46). Although phosphorylation levels of cTnI at Ser23/24 were significantly increased after dobutamine stimulation (155 ± 7% in WT + dobutamine vs. 100 ± 9% in WT without dobutamine, 161 ± 8% in TG + dobutamine vs. 102 ± 5% in TG without dobutamine; both P < 0.05), there were no significant changes either in basal phosphorylation level or in dobutamine-stimulated phosphorylation level between TG and WT mice (Fig. 8, C and D). The results indicate that impaired relaxation and prolonged IVRT and DT in left ventricles of TG mice are not associated with phosphorylation of cTnI at Ser23/24.

We further examined the effect of ß-agonist stimulation on left ventricular systolic and diastolic dynamics. The results demonstrated that dobutamine administration induced a significant increase in heart rate in both TG and WT mice (Fig. 9A). CO was elevated significantly in WT mice on dobutamine stimulation, in parallel with the increase of heart rate. In contrast, CO was not changed in TG mice after dobutamine administration (Fig. 9B). In the RCM cTnI^{His193} mice, left ventricular end-systolic volume (ESV) did not change whereas left ventricular EDV decreased significantly at age of 12 mo compared with WT mice at the same age (Fig. 9, C and D). This contributes to the decreased stroke volume that equals to EDV minus ESV. Dobutamine-stress increased cardiac contractility and decreased ESV in both WT and TG mice (Fig. 9D). While the treatment had little effect on EDV of WT mice, it significantly decreased EDV in TG mice (Fig. 9C).

**DISCUSSION**

We have generated a transgenic mouse model expressing the human RCM cTnI R192H mutation in adult cardiac muscle. The phenotype manifested in the cTnI^{193His} mice is very similar to that observed in RCM patients carrying the same mutation (30). Morphologically, the most dramatic change in cTnI^{193His} mice is ventricular restriction with decreased LVEDD due to shortened myocyte length. Functionally, the most significant changes are impaired relaxation manifested by prolonged IVRT and DT and restrictive physiology manifested by a reduced peak E’ velocity and hence a reversed E’/A’ on DTI. These data indicate that cTnI^{193His} mice provide a useful disease model for the study of human RCM. On the basis of longitudinal echocardiography investigation, the earliest signs in the RCM mice are the prolonged IVRT and restricted ventricles that start at age of 4 mo. It is also clear that no significant change of IVCT was detected in TG mice even at the age of 12 mo.

Doppler echocardiography has emerged as an important clinical tool to provide reliable and useful data for diastolic performance (6, 15). The noninvasive nature and high-resolution feature of Vevo 770 echocardiography allow us to longitudinally monitor heart function in mice, so it is commonly used to obtain detailed phenotypic assessment for understanding the functional impact in genetically altered mouse models (1, 8, 47, 53, 54). From 12 mo of investigation, we demon-
strated the pathophysiological development in the heart in RCM cTnI^{193His} mice, which progresses initially from abnormal relaxation gradually to diastolic dysfunction, and eventually to diastolic heart failure. The transmitral velocity pattern is the starting point of echocardiography assessment of left ventricular diastolic function, since it is easy to acquire and can rapidly distinguish normal from abnormal diastolic function in mice by E/A (early to late filling velocity ratio) (11, 12, 45). When relaxation impairs, early diastolic filling decreases progressively and a vigorous compensatory atrial contraction, i.e., atrial kick, occurs (Fig. 4). This results in a reversed E/A, increased DT, and prolonged IVRT (Fig. 7). It is observed that with disease progression left ventricular compliance becomes reduced and filling pressure begins to increase, leading to compensatory elevation of left atrial pressure with increase in early filling, so that the filling pattern looks relatively normal on 12-mo-old TG mice (pseudonormalization pattern, E/A > 1). In such cases, DTI is very useful to distinguish the pseudonormalization pattern from the normal filling pattern. Significantly decreased peak E' velocity and E'/A' < 1 in mitral annulus velocity define the pseudonormalization pattern with diastolic dysfunction. It should be pointed out that although the low concentration of isoflurane (∼1.5%) that is used to anesthetize the mice for stable data acquisition is thought to have minimal effects on ventricular diastolic function in mice (53), the heart rate at this condition is ∼450 beats/min, which is lower than that under conscious conditions. It is critical to apply the same conditions to both TG and WT experimental animals since the reduced heart rate may alter chamber size measurement.

The mortality rate in cTnI^{193His} mice is higher than that in their WT littermates. The cause of death is not clear, although some of the mice showed heart failure signs such as difficult breathing before death and some had an enlarged liver detected in autopsy. We found that 4 among 10 TG mice analyzed suffered from various degrees of enlarged liver. Hepatomegaly has been clinically reported in human patients suffering from RCM (4, 5). Our data suggest that cTnI mutation-caused diastolic dysfunction could result in right-sided heart failure in aged TG mice. Although no significant abnormality in ECG was found in TG mice during echocardiography examinations, we did find some ECG changes in some TG mice. It will be useful to further analyze ECG changes in TG mice.

Fig. 9. Cardiac responses in WT and TG mice to dobutamine stimulation. Dobutamine was given intraperitoneally at 1.5 μg/g body wt, and heart rate (A), CO (B), LVEDV (C), and LV end-systolic volume (LVESV) (D) before and after dobutamine administration were plotted individually for 5 WT and 5 TG mice.
mice in future studies. Impaired relaxation is the main manifestation in cTnI<sup>193His</sup> mice.

What is the mechanism underlying the damaged relaxation in myocytes carrying the cTnI-R193H mutation? An in vitro study using isolated rat cardiac myocytes infected with a recombinant adenovirus vector carrying the cTnI-R193H mutation reported that myofilaments incorporated with cTnI-R193H have a higher isometric tension than control myocytes at submaximal Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]) and cTnI-R193H causes a Ca<sup>2+</sup>-independent shortening of resting sarcomere length and slows relaxation (7). Both the in vitro study and our in vivo study found that the cell length was shorter in cardiac myocytes carrying the RCM cTnI mutation. The shortening of cardiac myocytes is caused by the increased basal mechanical tone without associated alteration in diastolic [Ca<sup>2+</sup>] i.e., RCM cTnI-R193H causes a calcium-independent shortening of resting sarcomere length (7). In addition, our present study also revealed that phosphorylation levels in cTnI at Ser23/24 were not changed in RCM cTnI-R193H compared with WT. Dobutamine can cause an increase of cTnI phosphorylation in both WT and TG mouse hearts. Interestingly, dobutamine stress can also cause a significant increase of heart rate in cTnI<sup>193His</sup> mice similar to that in WT control mice but did not increase CO as it did in WT mice, suggesting that the RCM cTnI<sup>193His</sup> hearts are able to respond to β-adrenergic signaling but CO fails to increase in response to dobutamine stimulation because of the increased diastolic tone. The decreased capacity for stress response may explain the higher mortality in RCM cTnI<sup>193His</sup> mice, although the penetration of the phenotypes of RCM cTnI R193H mutation in TG mice would depend on the combination of genetic and environmental factors as seen in RCM patients (30). No significant changes have been observed in Ca<sup>2+</sup> transients and Ca<sup>2+</sup> cycle-related proteins [Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX), sarc(endo)plasmic reticulum Ca<sup>2+</sup>-ATPase (SERCA), PLB] in myocytes incorporated with cTnI-R193H mutants (7). Further studies are needed to explore the Ca<sup>2+</sup> cycling changes with age in myocytes from cTnI<sup>193His</sup> mice.

Many studies have demonstrated the functional consequences of troponin mutations linked to HCM, DCM, or RCM and have shown that these mutations alter the regulatory properties of troponin complex, resulting in an increase or a decrease in Ca<sup>2+</sup> sensitivity of force generation that may primarily contribute to the pathogenesis of cardiomyopathies (14, 21, 26, 29, 33–36, 44, 48). Very interestingly, different mutations in the same TnI molecule can result in HCM or RCM, i.e., TnI HCM mutations (R145G, R145Q, R162W, G203S, K206Q) and TnI RCM mutations (L144Q, R145W, A171T, K178E, D190G, R192H). It is still unknown how HCM or RCM mutations are manifested in vastly distinct diseases. It may be possible that clinical diagnostic techniques lack the ability to differentiate subtypes that exist between these two diseases (35). The other explanation could be that the different mutations have a direct effect on troponin function, since RCM mutations have been found to have much greater Ca<sup>2+</sup>-sensitizing effects on force generation than TnI HCM mutations and structural changes have been observed in TnI RCM mutations (32).

Among the three major types of cardiomyopathy, RCM is the most malignant and the least studied (39). Most RCM patients eventually progress to overt heart failure (13, 32). Clinically most RCM cases are idiopathic with unknown causes. Targeted activation of p38 MAP kinase in ventricular myocytes resulted in a RCM in transgenic mice (24). The MAP kinase caused a severe RCM and premature death at 7–9 wk. The transgenic hearts exhibited marked interstitial fibrosis and expression of fetal marker genes characteristic of cardiac failure (24). Since stress-induced MAP p38 is activated in various forms of heart failure, it should be interesting to examine p38 MAP kinase activities in cardiac myocytes from cTnI<sup>193His</sup> mice at the late stages with heart failure signs. However, the molecular mechanism underlying TnI mutation-caused RCM is different from the RCM caused by overactivated MAP kinases. A recent in vitro study on RCM cTnI-R193H mutant myocytes indicates that events downstream of Ca<sup>2+</sup> handling are causal for the RCM cTnI-R193H defects and the thin filament is a unique target for possible therapeutic intervention (7). Hence, the RCM cTnI-R193H mutant mouse model investigated in the present study provides us with a useful tool for studies aimed at the treatment and prevention of myofibril protein mutation-caused RCM in humans.

**REFERENCES**


